Moxifloxacin was approved in Japan
On February 10, 2020, Chongqing Huapont Pharmaceutical Co., Ltd. obtained the "Notice of Pharmaceutical Compliance Investigation Results" issued by the Japanese competent authority PMDA (Pharmaceuticals and Medical Devices Agency). Moxifloxacin hydrochloride produced by Huapont had approved by PMDA. The approval indicated GMP management system of Huapont and the technical quality research of our product were certified, and also has a positive impact on the company's expansion into the Japanese pharmaceutical market.
On September 19, 2022, the completion and commissioning ceremony of a new base was held, the new base is located in Changshou District, Chongqing. The construction of Changshou Base started on October 8, 2019, after 2 years and 11 months of construction, the total construction area 89036.79㎡ was completed, including four buildings for API, four buildings for storage warehouses, one building fro QC, one power center and one sewage treatment station. All plants are operated by gravity flow and equipped with automatic control systems such as DCS, SIS, BMS and WMS.
Huapont Pharma was awarded the 2021 Outstanding Company for National Adverse Drug Reaction Monitoring and Evaluation
The National Adverse Drug Reaction Monitoring Center commended Huapont Pharm. Due to its outstanding for performing the main responsibility. Meanwhile, Huapont Pharm. is also the only pharmaceutical manufacturer in Chongqing that has been commended. Under the leadership of the Drug Safety Committee
From February 22 to February 25, 2022, and from March 1 to March 4, 2022, NMPA (National Medical Products Administration), Chongqing conducted on-site inspection for large-volume injection. The officers conducted a comprehensive inspection. including the R&D area and production site of the injection solution, specifically, the quality management and control at the site,
Huapont Pharm. was successfully approved as a municipal green factory recently by Chongqing Municipal Economic and Information Commission It is the recognition of the company's green development, healthy development and sustainable development. Huapont Pharm. Will always focus on the concept of green development, adhere to green manufacturing, vigorously promote our company's development towards low consumption, green and ecological, and strive to complete the creation of national green factories.
Our management system of intellectual property was inspected by Zhongbiaotong International Certification (Shenzhen) Co., Ltd. from December 8th to 10th. Huapont Management system of intellectual property was accredited as complying with the "GB/T 29490-2013 Enterprise Intellectual Property Management Specification". Huapont was certified with <Certificate of Intellectual Property Management System>.
Chongqing Municipal Drug Administration conducted an inspection for sterile preparation workshop of Huapont on December 1st ~ 2nd in 2021. During inspection, quality related management documentations were comprehensively and deeply reviewed,